All In Biotech

Free tool

FAERS Monitor: Varibar Pudding

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 208844 or its brand name (Varibar Pudding, Barium Sulfate). Reports on generic versions are filed under their own applications.

Reports

262

Serious

195

74% of reports

Hospitalization

115

Death reported

31

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • renal failure18
  • acute kidney injury17
  • urticaria16
  • chronic kidney disease15
  • diarrhoea15
  • rash14
  • dyspnoea13
  • vomiting13
  • drug hypersensitivity12
  • pruritus12
  • abdominal pain10
  • fatigue10
  • nausea10
  • no adverse event10
  • pain10

Reports by year received

View as table
YearReports
20052
20063
20073
20088
20094
20108
201112
201212
201317
201412
20159
201618
201723
201818
201916
202012
202118
202220
202318
202410
202513
20266

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,897 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
chronic kidney diseaseSignal1515.99.7195
renal failureSignal1810.97.0153
acute kidney injurySignal178.95.6113
urticariaSignal167.74.887
drug hypersensitivitySignal125.02.935
no adverse eventSignal104.42.423
abdominal painSignal103.51.915
rashSignal142.61.512
pruritusSignal122.51.410
vomitingSignal132.21.38
diarrhoea151.91.15
dyspnoea131.81.14
pain101.30.70
fatigue101.00.60
nausea101.00.60

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.